Published on 02/12/2025

Blister Packs and Foils: Unique E&L and Integrity Risks

Introduction to Extractables and Leachables (E&L) Risks

As pharmaceutical products undergo development, the importance of packaging as an integral component of drug safety cannot be overstated. Blister packs and foils, common forms of secondary packaging, introduce unique extractables and leachables (E&L) risks that must be meticulously evaluated. These risks stem from the potential migration of chemical substances from packaging into the product, compromising its quality and safety. This guide provides a structured approach to understanding E&L risks associated with blister packs and foils and outlines best practices for evaluating these risks under cGMP, USP, FDA, and EMA regulations.

In an increasingly regulated market, pharmaceutical companies are required to demonstrate compliance with regulatory expectations set forth by entities such as the FDA, EMA, and MHRA. A thorough understanding of analytical evaluation thresholds (AET), dose-based thresholds (DBT), and container closure integrity (CCI) are essential for compliance and patient safety.

Understanding Extractables and Leachables (E&L)

Extractables and leachables can be defined as follows:

• Extractables: Compounds that can be extracted from packaging materials under extreme conditions, which may not reflect normal handling but provide a worst-case scenario of what substances may migrate into the drug product.
• Leachables: Substances that migrate from the packaging into the drug product during normal storage and usage conditions.

The E&L evaluation aims to identify and quantify these substances to ensure their levels fall below acceptable limits, hence safeguarding the efficacy and safety of the drug product. Proper E&L risk assessment involves implementing a systematic approach to assess potential risks associated with different packaging types, including blister packs and foils.

The Role of Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

The Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT) serve as pivotal metrics in E&L risk assessments. The AET provides a threshold level for individual extractables that can be detected analytically while being non-significant in terms of potential patient risk. Conversely, the DBT corresponds to the threshold level of leachables based on the maximum intended dose of the drug product. These thresholds are vital in determining whether further toxicological assessment is required.

To perform AET and DBT calculations, one must consider the following:

• Drug Dosage: The maximum dose of the active pharmaceutical ingredient (API) as stipulated in the product information.
• Administration Frequency: The frequency at which the drug is administered to the patient.
• Patient Population: Consideration of the most sensitive patient cohorts, often including children, elderly, or patients with compromised health.

Example Calculation: For a drug administered at a dose of 100 mg per day, the AET might be determined according to the risk level determined in the risk assessment process, ensuring it remains compliant with regulatory frameworks such as the USP guidelines.

Conducting an E&L Risk Assessment

The E&L risk assessment is a documented systematic approach that includes the following stages:

1. Identification: Identify the primary packaging components (blister packs, foils) in contact with the drug product.
2. Selection of Analytical Methods: Determine appropriate analytical methods to evaluate extractables and leachables. Methods may include chromatographic techniques such as GC-MS, LC-MS, and FTIR.
3. Testing Execution: Execute the E&L testing through extraction studies that simulate real-world conditions. Performing the test under various conditions, such as temperature and time, helps ensure comprehensive data.
4. Data Analysis: Analyze the data to identify significant extractables and leachables. This includes comparison against established thresholds like AET and DBT.
5. Documentation and Reporting: Compile and document results in a format compliant with regulatory expectations for audit trails. All findings should be well-organized and defensible.

This risk assessment must follow relevant guidelines, including but not limited to the PQRI guidelines for E&L, ensuring it meets current Good Manufacturing Practice (cGMP) requirements.

Container Closure Integrity (CCI) Testing

Container closure integrity (CCI) assessment is a crucial step in ensuring that blister packs and foils effectively protect the drug product from external microbial contamination, moisture, and other environmental factors. CCI testing evaluates whether a container remains sealed and can safeguard its contents throughout its shelf life.

Various methods are utilized for CCI testing, including:

• Pressure Decay Testing: Measures the ability of the container to hold a known internal pressure and detects any leaks.
• Vacuum Decay Testing: Involves applying a vacuum to the package and monitoring for pressure changes that would indicate leakage.
• Colorimetric Testing: A method that can visually indicate whether a seal is intact, usually through dye ingress.
• Microbial Ingress Testing: Evaluates whether microbes can penetrate the container during its shelf life.

Ensuring CCI compliance involves following guidelines from regulatory bodies, particularly the EMA and respective national regulatory entities. Regular testing and rigorous documentation are essential to align with EU GMP Annex 1 standards.

Single-Use Systems Validation in E&L Assessment

Single-use systems (SUS) have become increasingly popular in the pharmaceutical industry, especially for bioprocessing applications. Their use raises unique E&L challenges that warrant specific validation strategies. The importance of validating single-use systems to mitigate E&L risks lies in the quality of materials and their interaction with the drug product.

Key validation steps for single-use systems include:

• Material Characterization: Understand the chemical composition of materials within the single-use system, focusing on plastics and other polymers.
• E&L Testing: Similar to traditional packaging, perform extractables testing to predict leachables under intended use conditions.
• Compatibility Studies: Assess the compatibility of single-use systems with the drug product to ensure integrity and efficacy throughout the lifecycle.

Every aspect of validation should be validated and documented in compliance with FDA process validation guidance and aligned with best practices in the pharmaceutical industry.

Implementation and Regulatory Considerations

When implementing E&L risk assessments, thorough documentation and adherence to regulatory frameworks are paramount. The successful integration of newly validated blister packs, foils, and single-use systems must reflect a commitment to maintaining high standards of compliance. The following considerations must be observed:

• Regulatory Compliance: Ensure that all methods and findings align with the expected standards from the FDA, EMA, MHRA, and PIC/S.
• Continuous Monitoring: After initial validation, continuous monitoring of E&L risks and CCI must occur to adapt to new insights from the scientific community and regulatory updates.
• Training and Development: Regularly train personnel involved in packaging and quality management systems to ensure comprehensive understanding and compliance with E&L assessment protocols.

Conclusion: Ensuring Patient Safety through Robust Evaluation

The complexities involved in E&L assessment, CCI testing, and the validation of blister packs and foils underscore the significant responsibility pharmaceutical professionals bear in ensuring product safety. By rigorously applying the guidelines and methodologies outlined in this tutorial, companies can systematically mitigate E&L risks. Adhering to regulatory expectations and employing comprehensive E&L risk assessments, along with CCI testing and integration of validated single-use systems, are key to ensuring quality and compliance in pharmaceutical packaging systems.

Ultimately, ensuring patient safety through robust evaluations and continuous improvement represents the pinnacle of pharmaceutical quality assurance efforts.